





## Active substances set

**Search phrase:** Malignant pancreatic cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Malignant pancreatic cancer

<b>Nab-paclitaxel</b>	Nab-Paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.	 <b>FULL REIMBURSEMENT</b>  <b>ESMO</b>
<b>Irinotecan hydrochloride trihydrate</b>	Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy	 <b>FULL REIMBURSEMENT</b>  <b>ESMO</b>